A
Anthony Rocco Imondi
Researcher at Battelle Memorial Institute
Publications - 6
Citations - 254
Anthony Rocco Imondi is an academic researcher from Battelle Memorial Institute. The author has contributed to research in topics: Plenum chamber & Chemotherapy. The author has an hindex of 5, co-authored 6 publications receiving 253 citations.
Papers
More filters
Patent
Formulation and method for treating neoplasms by inhalation
Michael E. Placke,Anthony Rocco Imondi,Michael J. Brooker,John E. Frye,Praful K. Shah,Douglas R. Flanagan,Maureen D. Donovan +6 more
TL;DR: In this article, a formulation, method, and apparatus for treating neoplasms such as cancer by administering a pharmaceutically effective amount of highly toxic composition by inhalation, wherein the composition is a non-encapsulated antineoplastic drug.
Patent
Pulmonary dosing system and method
TL;DR: In this article, a pulmonary dosing system and method for supplying to a patient a predetermined amount of respirable therapeutically active material is disclosed, which comprises a patient interface to introduce the material into the patient's lungs and an apparatus for providing pulsed amounts of the material to a plenum chamber.
Journal Article
Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
Anthony Rocco Imondi,P Della Torre,Guy Mazue,T M Sullivan,T L Robbins,L M Hagerman,A Podestà,G Pinciroli +7 more
TL;DR: DZR is highly effective in attenuating the cardiomyopathy caused by DOX, but dose ratios of DZR:DOX capable of providing total or nearly complete cardioprotection at low doses of DOX are less efficacious at higher doses ofdoxorubicin.
Journal ArticleDOI
Cardioprotection by dexrazoxane in rats treated with doxorubicin and paclitaxel.
TL;DR: The results suggest that PTX does not exacerbate the chronic cardiomyopathy caused by DOX and when added to the DOX+PTX combination, DZR retains its protective activity against DOX-induced cardiotoxicity without increasing noncardiac toxicity.
Journal ArticleDOI
PNU-159548, a novel cytotoxic antitumor agent with a low cardiotoxic potential.
Paola Della Torre,A Podestà,Anthony Rocco Imondi,D Moneta,Umberto Sammartini,Claudio Arrigoni,Andrea Terron,Marco Brughera +7 more
TL;DR: The novel cytotoxic antitumor derivative, PNU-159548, is significantly less cardiotoxic than doxorubicin at equimyelosuppressive doses and an excellent candidate for clinical development in oncology.